Delled - LaFleur produces France's first cannabis extracts for medical use

Delled - LaFleur was already one of the pioneers of the medical cannabis sector in France. The company has just announced that it has grown and released a batch of medical cannabis extract intended for the manufacture of an oral form of cannabis-based treatment. This milestone marks a turning point in the history of the company and of medical cannabis in France, which is moving inexorably closer to becoming a reality.

Cultivation, extraction then destruction

The company has invested in state-of-the-art facilities to guarantee a safe, controlled environment for cannabis cultivation and to be able to work on the European market. Building on its track record in horticultural LEDs, Delled - LaFleur grows its Cannabis plants using a proprietary system for controlling the growing and drying environment called Hortimind.

Extraction was also carried out in-house to obtain a extract of pure, highly concentrated medical cannabis. This method not only preserves the plant's therapeutic properties, but also eliminates unwanted impurities.

Delled - LaFleur has also implemented rigorous quality control measures throughout the production process. Each batch of medical cannabis extract undergoes thorough testing for cannabinoid content, terpene profiles, microbial contaminants, heavy metals and residual solvents. The company monitors these variables in its raw materials using high-performance liquid chromatography (HPLC) and gas chromatography (GC-MS), a method that is also used in the manufacture of its products. service it already offers to companies who would like to have their flowers or CBD extracts analyzed.

The batches were then «released», a jargon used to mean that the batches had been certified by a qualified person and could be distributed to patients. As medical cannabis is not yet widely available in France, and experimentation is taking place abroad, part of these technical batches will be destroyed. The other part will be integrated into technical batches of an oral formulation, in order to stabilize them and observe the product's behavior over time, in particular the degradation of the active ingredients present. The data collected will then be sent to the Agence nationale de sécurité du médicament et des produits de santé (ANSM) to validate the products for post-experimentation.

Delled - LaFleur has successfully completed a proof of concept of its capabilities and is already in a position to supply its first batches of medical cannabis to French patients.